Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis

被引:80
作者
Li, JJ [1 ]
Fang, CH
机构
[1] Wuhan Univ, Sch Med, Benmin Hosp, Wuhan 430060, Peoples R China
[2] Tsinghua Univ, Sch Med, Affilliated Hosp 1, Ctr Heart, Beijing 100016, Peoples R China
关键词
D O I
10.1016/j.mehy.2004.01.029
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The term 'atheroma', a Latin word was first used in 1755 by Albrecht von Halles to designate the plaque deposited on the innermost layer of systemic artery watts. In 1940, however, Felix Marchand suggested the word 'atherosclerosis' should be better instead of 'atheroma', which is derived from two Greek roots: athere means gruel or porridge and sclerosis signifies hardening. It is obviously an improvement over the older designation arteriosclerosis. Atherosclerosis is still used up to data because it describes the two components of plaque: the lipid-filled core of atheroma encased in a shell of sclerosis or fibrosis, which presents the feature of atherosclerotic structure. Although atherosclerosis has been considered to be multi-factorial disease in which genetic, environmental, metabolic factors have been implicated, the gaps remain in our knowledge of the etiopathogenesis of atherosclerosis. More recently, there is mounting evidence that inflammation plays an important role in the initiation, development as well as evolution of atherosclerosis. The data from animals as well as humans indicated that an inflammatory process was involved in all stages of atherosclerosis appeared in different clinical settings, including atheromatous development, plaque rupture, restenotic process. The anti-inflammatory approach has been showed as one of the most promising strategies for atherosclerosis, such as statin intervention. Based on evidence and in Light of the new understanding that inflammation is an intrinsic part of the process, we would like to propose a further change of nomenclature, call the disease atheroscleritis. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:100 / 102
页数:3
相关论文
共 16 条
[1]   Increased C-reactive protein levels in patients with in-stent restenosis and its implications [J].
Angioi, M ;
Abdelmouttaleb, I ;
Rodriguez, RM ;
Aimone-Gastin, I ;
Adjalla, C ;
Guéant, JL ;
Danchin, N .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (10) :1189-+
[2]  
CAPRON L, 1996, REV PRATICIEN, V46, P533
[3]   C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases [J].
Li, JJ ;
Fang, CH .
MEDICAL HYPOTHESES, 2004, 62 (04) :499-506
[4]   Silent myocardial ischemia may be related to inflammatory response [J].
Li, JJ .
MEDICAL HYPOTHESES, 2004, 62 (02) :252-256
[5]   Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia [J].
Li, JJ ;
Chen, MZ ;
Chen, X ;
Fang, CH .
CLINICAL CARDIOLOGY, 2003, 26 (10) :472-476
[6]   Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide [J].
Li, JJ ;
Chen, XJ .
CORONARY ARTERY DISEASE, 2003, 14 (04) :329-334
[7]   Elevated level of plasma C-reactive protein in patients with unstable angina: Its relations with coronary stenosis and lipid profile [J].
Li, JJ ;
Jiang, H ;
Huang, CX ;
Fang, CH ;
Tang, QZ ;
Xia, H ;
Liu, J ;
Li, GS .
ANGIOLOGY, 2002, 53 (03) :265-272
[8]  
LI JJ, 2004, IN PRESS HEAT LUNG C
[9]   C-reactive protein: a critical update [J].
Pepys, MB ;
Hirschfield, GM .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (12) :1805-1812
[10]   Direct evidence for cytokine involvement in neointimal hyperplasia [J].
Rectenwald, JE ;
Moldawer, LL ;
Huber, TS ;
Seeger, JM ;
Ozaki, CK .
CIRCULATION, 2000, 102 (14) :1697-1702